latest news releases from the newsroom
Tele2 in Luxembourg Launches the First Worldwide Free TV for 3G Phones
NEW YORK and STOCKHOLM, Sweden, March 18, 2005 (PRIMEZONE) -- Tele2 AB ("Tele2") (Nasdaq:TLTOA) (Nasdaq:TLTOB) (Stockholmsborsen: TEL2A and TEL2B), the leading alternative pan-European telecommunications company, today announced that it has launched the first worldwide free TV station available on 3G mobile phones, via its own TV channel Tango.TV (TTV).
Skandia Denmark Sharpens its Competitive Edge
STOCKHOLM, Sweden, March 18, 2005 (PRIMEZONE) -- Skandia is now beginning the work on creating a joint marketing organisation for the Danish market. The aim is to enable customers to access their entire portfolio of business with Skandia through a single phone call, visit to a website or contact person. Life assurance, unit linked assurance, banking services and healthcare insurance will be offered individually or in combination -- depending on the customer's needs.
Crucell Secures Exclusive Patent License from NIH to Commercialize Ebola Vaccines
LEIDEN, Netherlands, March 18, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has obtained an exclusive license to certain patents of the National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services, to develop and commercialize recombinant vaccines against Ebola.
Boehringer Ingelheim and MorphoSys Enlarge Collaboration
MARTINSRIED, Germany, March 18, 2005 (PRIMEZONE) -- Boehringer Ingelheim and MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) announced today an expansion of their existing cooperation involving both research and therapeutic applications. Under the new contract, Boehringer Ingelheim has acquired an option to receive several exclusive licenses on new therapeutic antibody programs. The two companies presently have two therapeutic antibody programs in joint collaboration. Additionally, Boehringer Ingelheim will obtain access to MorphoSys' HuCAL GOLD(r) library for research purposes at a number of the firm's research facilities. The first installation site is intended to be Boehringer Ingelheim's site in Vienna, Austria. MorphoSys will receive a technology access fee, annual license fees and optional R&D funding over the five-year collaboration term. For therapeutic antibodies emerging from the collaboration, Boehringer Ingelheim will pay milestone fees and royalties to MorphoSys. Financial details of the agreement were not disclosed.
Taitron Components Inc
Taitron Reports Fourth Quarter and Year-End 2004 Results
LOS ANGELES, March 17, 2005 (PRIMEZONE) -- Taitron Components Incorporated (Nasdaq:TAIT) today announced financial results for the fourth quarter and year-ended December 31, 2004. Net sales for 2004 were $9.4 million, compared with $9.5 million for 2003. Net loss was $248,000 for 2004, or $0.05 loss per basic and diluted share, compared with a net loss of $387,000 for 2003, or $0.07 loss per basic and diluted share. The Company also reported net sales of $1.8 million for the fourth quarter in 2004, compared with $1.9 million for the same period of 2003. Net loss was $311,000 for the fourth quarter of 2004, or $0.06 loss per basic and diluted share, compared with net loss of $523,000 for the same period of 2003, or $0.09 loss per basic and diluted share.